Smith-Midland Key Executives
This section highlights Smith-Midland's key executives, including their titles and compensation details.
Find Contacts at Smith-Midland
(Showing 0 of )
Smith-Midland Earnings
This section highlights Smith-Midland's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Smith-Midland Corporation, through its subsidiaries, invents, develops, manufactures, markets, leases, licenses, sells, and installs precast concrete products primarily for use in the construction, highway, utilities, and farming industries. It offers SlenderWall, a patented, lightweight, energy efficient concrete and steel exterior wall panel for use in building construction; Sierra Wall that provides sound and sight barrier for use alongside highways around residential, industrial, and commercial properties; J-J Hooks highway safety barriers for use on roadways to separate lanes of traffic in construction work zone or traffic control purposes; and Easi-Set precast building and Easi-Span expandable precast buildings for use in housing communications operations, traffic control systems, and mechanical and electrical stations. The company also provides Easi-Set utility vaults for house equipment, such as cable, telephone, or traffic signal equipment, and for underground storage, as well as custom-built utility vaults for special needs; SoftSound soundwall panels to absorb highway noise; Beach Prisms, an erosion control module for seawalls and jetties; and H2Out secondary drainage systems for panelized exterior cladding. In addition, it licenses its proprietary products in Canada, Australia, Belgium, Mexico, New Zealand, and Trinidad. The company markets its products through in-house sales force and independent sales representatives to contractors performing public and private construction contracts, such as construction of commercial buildings, public and private roads and highways, airports, and municipal utilities; and federal, state, and local transportation authorities. Smith-Midland Corporation was incorporated in 1960 and is based in Midland, Virginia.
$32.40
Stock Price
$171.87M
Market Cap
247
Employees
Midland, VA
Location
Financial Statements
Access annual & quarterly financial statements for Smith-Midland, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $59.58M | $50.13M | $50.64M | $43.86M | $46.69M |
| Cost of Revenue | $48.93M | $40.66M | $36.22M | $32.82M | $36.72M |
| Gross Profit | $10.65M | $9.47M | $14.42M | $11.04M | $9.97M |
| Gross Profit Ratio | 17.88% | 18.89% | 28.50% | 25.17% | 21.35% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $5.99M | $5.55M | $5.42M | $4.99M | $4.89M |
| Selling and Marketing Expenses | $3.54M | $3.06M | $2.84M | $2.29M | $2.54M |
| Selling General and Administrative Expenses | $9.53M | $8.62M | $8.25M | $7.28M | $7.42M |
| Other Expenses | $- | $228.00K | $72.00K | $82.00K | $55.00K |
| Operating Expenses | $9.53M | $8.62M | $8.25M | $7.28M | $7.42M |
| Cost and Expenses | $58.46M | $49.28M | $44.47M | $40.10M | $44.15M |
| Interest Income | $24.00K | $14.00K | $35.00K | $35.00K | $40.00K |
| Interest Expense | $255.00K | $260.00K | $190.00K | $217.00K | $179.00K |
| Depreciation and Amortization | $2.38M | $2.89M | $2.67M | $2.41M | $1.79M |
| EBITDA | $3.96M | $4.10M | $8.84M | $6.17M | $4.34M |
| EBITDA Ratio | 6.64% | 7.93% | 17.67% | 14.34% | 9.50% |
| Operating Income | $1.12M | $854.00K | $6.17M | $3.76M | $2.55M |
| Operating Income Ratio | 1.88% | 1.70% | 12.18% | 8.57% | 5.45% |
| Total Other Income Expenses Net | $205.00K | $91.00K | $2.93M | $33.00K | $-48.00K |
| Income Before Tax | $1.32M | $945.00K | $9.09M | $3.79M | $2.51M |
| Income Before Tax Ratio | 2.22% | 1.89% | 17.96% | 8.65% | 5.37% |
| Income Tax Expense | $528.00K | $145.00K | $1.52M | $1.13M | $549.00K |
| Net Income | $795.00K | $800.00K | $7.57M | $2.67M | $1.95M |
| Net Income Ratio | 1.33% | 1.60% | 14.95% | 6.08% | 4.17% |
| EPS | $0.15 | $0.15 | $1.45 | $0.51 | $0.38 |
| EPS Diluted | $0.15 | $0.15 | $1.45 | $0.51 | $0.38 |
| Weighted Average Shares Outstanding | 5.26M | 5.23M | 5.21M | 5.18M | 5.14M |
| Weighted Average Shares Outstanding Diluted | 5.29M | 5.25M | 5.23M | 5.19M | 5.15M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.58M | $19.64M | $16.76M | $16.39M | $15.65M | $14.70M | $12.84M | $14.49M | $11.96M | $13.25M | $10.44M | $10.02M | $13.10M | $12.31M | $15.22M | $11.07M | $12.52M | $10.45M | $9.82M | $12.44M |
| Cost of Revenue | $17.00M | $14.51M | $12.85M | $13.27M | $12.07M | $12.91M | $10.68M | $11.98M | $9.87M | $10.02M | $8.79M | $7.83M | $9.90M | $8.99M | $9.50M | $7.85M | $8.67M | $8.07M | $8.22M | $9.44M |
| Gross Profit | $6.58M | $5.13M | $3.91M | $3.12M | $3.58M | $1.79M | $2.17M | $2.51M | $2.08M | $3.23M | $1.65M | $2.18M | $3.20M | $3.31M | $5.72M | $3.22M | $3.84M | $2.38M | $1.60M | $3.00M |
| Gross Profit Ratio | 27.89% | 26.10% | 23.30% | 19.10% | 22.90% | 12.20% | 16.90% | 17.30% | 17.40% | 24.40% | 15.80% | 21.80% | 24.40% | 26.90% | 37.60% | 29.12% | 30.69% | 22.75% | 16.28% | 24.10% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $1.72M | $1.67M | $1.55M | $1.57M | $1.19M | $1.88M | $1.35M | $1.75M | $1.23M | $1.41M | $1.16M | $1.54M | $1.22M | $1.34M | $1.32M | $1.44M | $1.27M | $1.23M | $1.05M | $1.41M |
| Selling and Marketing Expenses | $1.01M | $791.00K | $853.00K | $1.01M | $888.00K | $883.00K | $762.00K | $828.00K | $849.00K | $725.00K | $662.00K | $826.00K | $719.00K | $696.00K | $595.00K | $610.00K | $521.00K | $574.00K | $591.00K | $612.00K |
| Selling General and Administrative Expenses | $2.73M | $2.46M | $2.40M | $2.58M | $2.08M | $2.77M | $2.11M | $2.58M | $2.08M | $2.13M | $1.82M | $2.36M | $1.93M | $2.04M | $1.92M | $2.05M | $1.79M | $1.80M | $1.64M | $2.02M |
| Other Expenses | $- | $- | $44.00K | $18.00K | $16.00K | $32.00K | $25.00K | $20.00K | $26.00K | $162.00K | $20.00K | $31.00K | $8.00K | $39.00K | $-7.00K | $41.00K | $22.00K | $16.00K | $4.00K | $20.00K |
| Operating Expenses | $2.73M | $2.46M | $2.40M | $2.58M | $2.08M | $2.77M | $2.11M | $2.58M | $2.08M | $2.13M | $1.82M | $2.36M | $1.93M | $2.04M | $1.92M | $2.05M | $1.79M | $1.80M | $1.64M | $2.02M |
| Cost and Expenses | $19.73M | $16.97M | $15.25M | $15.85M | $14.15M | $15.68M | $12.79M | $14.56M | $11.95M | $12.16M | $10.61M | $10.20M | $11.83M | $11.03M | $11.42M | $9.89M | $10.47M | $9.88M | $9.87M | $11.47M |
| Interest Income | $22.00K | $7.00K | $8.00K | $7.00K | $6.00K | $5.00K | $6.00K | $5.00K | $3.00K | $3.00K | $3.00K | $6.00K | $10.00K | $10.00K | $9.00K | $9.00K | $8.00K | $9.00K | $9.00K | $9.00K |
| Interest Expense | $56.00K | $59.00K | $60.00K | $63.00K | $64.00K | $64.00K | $64.00K | $73.00K | $69.00K | $71.00K | $48.00K | $45.00K | $47.00K | $56.00K | $42.00K | $51.00K | $53.00K | $57.00K | $56.00K | $52.00K |
| Depreciation and Amortization | $702.00K | $653.00K | $641.00K | $583.00K | $619.00K | $582.00K | $594.00K | $754.00K | $727.00K | $697.00K | $703.00K | $695.00K | $658.00K | $672.00K | $646.00K | $621.00K | $611.00K | $608.00K | $572.00K | $472.00K |
| EBITDA | $4.60M | $3.33M | $2.15M | $1.24M | $2.12M | $-246.00K | $648.00K | $720.00K | $731.00K | $1.79M | $592.00K | $577.00K | $1.93M | $1.95M | $4.45M | $1.80M | $2.66M | $1.18M | $579.00K | $1.49M |
| EBITDA Ratio | 19.51% | 16.94% | 12.83% | 6.86% | 13.69% | -6.42% | 5.29% | 4.87% | 6.36% | 14.77% | 5.30% | 5.52% | 14.84% | 16.24% | 29.24% | 16.70% | 21.49% | 11.54% | 5.53% | 11.85% |
| Operating Income | $3.85M | $2.67M | $1.51M | $542.00K | $1.50M | $-981.00K | $85.00K | $-49.00K | $33.00K | $1.10M | $-173.00K | $-179.00K | $1.27M | $1.28M | $3.80M | $1.18M | $2.05M | $573.00K | $-42.00K | $973.00K |
| Operating Income Ratio | 16.32% | 13.61% | 9.01% | 3.31% | 9.60% | -6.67% | 0.66% | -0.34% | 0.28% | 8.27% | -1.66% | -1.79% | 9.68% | 10.38% | 24.98% | 10.64% | 16.37% | 5.48% | -0.43% | 7.82% |
| Total Other Income Expenses Net | $-4.00K | $-60.00K | $-5.00K | $56.00K | $11.00K | $89.00K | $49.00K | $-33.00K | $-11.00K | $121.00K | $14.00K | $16.00K | $2.87M | $35.00K | $6.00K | $74.00K | $-31.00K | $-2.00K | $-7.00K | $-7.00K |
| Income Before Tax | $3.84M | $2.61M | $1.50M | $598.00K | $1.51M | $-892.00K | $103.00K | $-107.00K | $-7.00K | $1.22M | $-159.00K | $-163.00K | $4.14M | $1.31M | $3.81M | $1.25M | $2.02M | $571.00K | $-49.00K | $966.00K |
| Income Before Tax Ratio | 16.30% | 13.31% | 8.98% | 3.65% | 9.67% | -6.07% | 0.80% | -0.74% | -0.06% | 9.18% | -1.52% | -1.63% | 31.57% | 10.67% | 25.02% | 11.31% | 16.12% | 5.46% | -0.50% | 7.76% |
| Income Tax Expense | $694.00K | $632.00K | $357.00K | $368.00K | $247.00K | $-110.00K | $23.00K | $-111.00K | $-12.00K | $307.00K | $-40.00K | $-187.00K | $442.00K | $328.00K | $941.00K | $539.00K | $469.00K | $130.00K | $-11.00K | $185.00K |
| Net Income | $3.15M | $1.98M | $1.15M | $230.00K | $1.27M | $-782.00K | $80.00K | $4.00K | $5.00K | $910.00K | $-119.00K | $24.00K | $3.69M | $985.00K | $2.87M | $713.00K | $1.55M | $441.00K | $-38.00K | $781.00K |
| Net Income Ratio | 13.36% | 10.09% | 6.85% | 1.40% | 8.09% | -5.32% | 0.62% | 0.03% | 0.04% | 6.87% | -1.14% | 0.24% | 28.20% | 8.00% | 18.84% | 6.44% | 12.38% | 4.22% | -0.39% | 6.28% |
| EPS | $0.59 | $0.37 | $0.22 | $0.04 | $0.24 | $-0.15 | $0.02 | $0.00 | $0.00 | $0.17 | $-0.02 | $0.00 | $0.71 | $0.19 | $0.55 | $0.13 | $0.30 | $0.09 | $-0.01 | $0.14 |
| EPS Diluted | $0.59 | $0.37 | $0.21 | $0.04 | $0.24 | $-0.15 | $0.02 | $0.00 | $0.00 | $0.17 | $-0.02 | $0.00 | $0.71 | $0.19 | $0.55 | $0.13 | $0.30 | $0.09 | $-0.01 | $0.14 |
| Weighted Average Shares Outstanding | 5.30M | 5.32M | 5.31M | 5.26M | 5.26M | 5.26M | 5.26M | 5.26M | 5.23M | 5.23M | 5.23M | 5.82M | 5.20M | 5.20M | 5.20M | 5.48M | 5.18M | 5.18M | 5.18M | 5.17M |
| Weighted Average Shares Outstanding Diluted | 5.30M | 5.32M | 5.35M | 5.29M | 5.30M | 5.26M | 5.29M | 5.26M | 5.29M | 5.27M | 5.23M | 5.28M | 5.22M | 5.22M | 5.21M | 5.20M | 5.18M | 5.18M | 5.18M | 5.31M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $9.18M | $6.73M | $13.49M | $8.76M | $1.36M |
| Short Term Investments | $- | $- | $- | $1.23M | $1.18M |
| Cash and Short Term Investments | $9.18M | $6.73M | $13.49M | $9.99M | $2.54M |
| Net Receivables | $17.73M | $17.69M | $10.86M | $10.54M | $13.46M |
| Inventory | $5.15M | $3.82M | $2.85M | $2.19M | $2.24M |
| Other Current Assets | $1.27M | $706.00K | $551.00K | $615.00K | $784.00K |
| Total Current Assets | $33.33M | $28.94M | $27.75M | $23.34M | $19.03M |
| Property Plant Equipment Net | $27.68M | $25.12M | $21.93M | $18.60M | $17.73M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $1.47M | $2.09M | $1.91M | $2.49M |
| Other Non-Current Assets | $343.00K | $-1.22M | $1.56M | $2.64M | $2.86M |
| Total Non-Current Assets | $28.02M | $25.37M | $25.57M | $23.16M | $23.08M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $61.35M | $54.31M | $53.33M | $46.50M | $42.12M |
| Account Payables | $7.34M | $5.82M | $2.07M | $1.87M | $3.18M |
| Short Term Debt | $679.00K | $772.00K | $551.00K | $910.00K | $1.09M |
| Tax Payables | $473.00K | $146.00K | $2.03M | $470.00K | $- |
| Deferred Revenue | $2.72M | $2.98M | $3.78M | $2.34M | $2.97M |
| Other Current Liabilities | $4.81M | $2.25M | $3.02M | $3.88M | $3.44M |
| Total Current Liabilities | $16.02M | $11.22M | $13.91M | $8.90M | $9.60M |
| Long Term Debt | $5.09M | $5.78M | $3.80M | $7.10M | $4.38M |
| Deferred Revenue Non-Current | $4.42M | $2.17M | $1.86M | $600.00K | $241.00K |
| Deferred Tax Liabilities Non-Current | $1.65M | $2.08M | $1.96M | $2.46M | $1.89M |
| Other Non-Current Liabilities | $- | $- | $- | $3.79M | $5.18M |
| Total Non-Current Liabilities | $11.17M | $10.03M | $7.67M | $13.95M | $11.69M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $27.19M | $21.26M | $21.57M | $22.85M | $21.29M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $54.00K | $53.00K | $53.00K | $52.00K | $52.00K |
| Retained Earnings | $26.39M | $25.66M | $24.86M | $17.29M | $14.64M |
| Accumulated Other Comprehensive Income Loss | $-0 | $-0 | $-0 | $-0 | $-10.00K |
| Other Total Stockholders Equity | $7.71M | $7.34M | $6.83M | $6.30M | $6.15M |
| Total Stockholders Equity | $34.16M | $33.05M | $31.75M | $23.65M | $20.82M |
| Total Equity | $34.16M | $33.05M | $31.75M | $23.65M | $20.82M |
| Total Liabilities and Stockholders Equity | $61.35M | $54.31M | $53.33M | $46.50M | $42.12M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $61.35M | $54.31M | $53.33M | $46.50M | $42.12M |
| Total Investments | $- | $- | $- | $1.23M | $1.18M |
| Total Debt | $5.77M | $6.47M | $4.40M | $7.92M | $5.39M |
| Net Debt | $-3.40M | $-256.00K | $-9.09M | $-840.00K | $4.02M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $9.01M | $7.29M | $6.80M | $9.18M | $5.85M | $4.73M | $3.94M | $6.73M | $10.81M | $12.43M | $14.82M | $13.49M | $14.99M | $13.19M | $12.53M | $8.76M | $7.45M | $4.40M | $2.20M | $1.36M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.24M | $1.24M | $1.23M | $1.23M | $1.21M | $1.19M | $1.16M | $1.18M |
| Cash and Short Term Investments | $9.01M | $7.29M | $6.80M | $9.18M | $5.85M | $4.73M | $3.94M | $6.73M | $10.81M | $12.43M | $14.82M | $13.49M | $16.24M | $14.44M | $13.76M | $9.99M | $8.66M | $5.59M | $3.36M | $2.54M |
| Net Receivables | $18.76M | $18.11M | $20.69M | $17.73M | $18.56M | $17.78M | $20.88M | $17.69M | $13.63M | $13.46M | $12.92M | $10.86M | $13.05M | $12.46M | $11.72M | $10.54M | $10.58M | $11.55M | $10.86M | $13.46M |
| Inventory | $6.24M | $6.67M | $6.95M | $5.15M | $4.21M | $4.75M | $4.99M | $3.82M | $3.98M | $3.53M | $3.33M | $2.85M | $3.20M | $2.74M | $2.35M | $2.19M | $2.16M | $2.11M | $2.17M | $2.24M |
| Other Current Assets | $979.00K | $1.65M | $1.25M | $1.27M | $1.27M | $1.21M | $776.00K | $706.00K | $622.00K | $472.00K | $443.00K | $551.00K | $622.00K | $558.00K | $528.00K | $615.00K | $838.00K | $845.00K | $708.00K | $784.00K |
| Total Current Assets | $34.99M | $33.71M | $35.69M | $33.33M | $29.89M | $28.48M | $30.58M | $28.94M | $29.04M | $29.89M | $31.51M | $27.75M | $33.11M | $30.20M | $28.36M | $23.34M | $22.24M | $20.10M | $17.10M | $19.03M |
| Property Plant Equipment Net | $31.19M | $29.88M | $28.83M | $27.68M | $27.41M | $26.89M | $25.68M | $25.12M | $24.16M | $22.91M | $21.63M | $21.93M | $18.25M | $18.61M | $18.53M | $18.60M | $18.92M | $19.24M | $18.00M | $17.73M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $2.28M | $- | $- | $- | $1.47M | $- | $- | $- | $2.09M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $444.00K | $451.00K | $337.00K | $343.00K | $349.00K | $356.00K | $243.00K | $-1.22M | $1.07M | $2.22M | $3.43M | $1.56M | $3.89M | $4.11M | $4.32M | $4.56M | $4.77M | $4.99M | $5.20M | $5.35M |
| Total Non-Current Assets | $31.63M | $30.34M | $29.16M | $30.31M | $27.76M | $27.24M | $25.92M | $25.37M | $25.23M | $25.12M | $25.06M | $25.57M | $22.14M | $22.72M | $22.85M | $23.16M | $23.70M | $24.23M | $23.20M | $23.08M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $66.63M | $64.05M | $64.85M | $63.63M | $57.65M | $55.72M | $56.50M | $54.31M | $54.28M | $55.01M | $56.57M | $53.33M | $55.25M | $52.92M | $51.21M | $46.50M | $45.93M | $44.33M | $40.30M | $42.12M |
| Account Payables | $5.43M | $5.40M | $6.94M | $7.34M | $5.48M | $5.68M | $6.44M | $5.82M | $4.58M | $3.73M | $3.52M | $2.07M | $3.17M | $2.94M | $2.57M | $1.87M | $2.50M | $3.12M | $2.67M | $3.18M |
| Short Term Debt | $677.00K | $692.00K | $708.00K | $722.00K | $711.00K | $731.00K | $764.00K | $695.00K | $797.00K | $797.00K | $789.00K | $557.00K | $662.00K | $3.33M | $1.48M | $825.00K | $985.00K | $2.22M | $1.01M | $1.01M |
| Tax Payables | $- | $841.00K | $831.00K | $473.00K | $235.00K | $- | $168.00K | $146.00K | $115.00K | $122.00K | $1.99M | $2.03M | $1.49M | $1.04M | $1.43M | $470.00K | $305.00K | $- | $- | $- |
| Deferred Revenue | $2.79M | $3.09M | $3.22M | $2.72M | $4.59M | $4.98M | $4.50M | $2.98M | $3.51M | $2.98M | $3.69M | $3.78M | $4.68M | $3.45M | $2.94M | $2.34M | $2.21M | $2.44M | $2.24M | $2.97M |
| Other Current Liabilities | $3.71M | $4.86M | $5.69M | $4.77M | $4.35M | $4.60M | $3.81M | $2.32M | $3.36M | $5.17M | $5.88M | $3.02M | $4.66M | $4.10M | $4.11M | $2.76M | $4.07M | $3.12M | $2.30M | $2.56M |
| Total Current Liabilities | $12.61M | $14.88M | $17.39M | $16.02M | $12.93M | $13.01M | $13.19M | $11.22M | $10.86M | $11.48M | $14.57M | $13.91M | $13.03M | $14.04M | $11.68M | $8.90M | $9.47M | $10.08M | $7.72M | $9.60M |
| Long Term Debt | $4.63M | $4.77M | $4.93M | $5.09M | $5.27M | $5.44M | $5.59M | $5.78M | $6.00M | $6.18M | $6.36M | $3.80M | $4.02M | $4.13M | $6.22M | $7.10M | $7.19M | $6.22M | $4.93M | $4.38M |
| Deferred Revenue Non-Current | $- | $5.57M | $5.57M | $4.42M | $3.55M | $2.63M | $2.48M | $2.17M | $2.54M | $2.60M | $1.93M | $1.86M | $1.28M | $1.42M | $804.00K | $600.00K | $523.00K | $512.00K | $117.00K | $241.00K |
| Deferred Tax Liabilities Non-Current | $1.65M | $1.65M | $1.65M | $3.94M | $2.09M | $2.18M | $2.09M | $2.08M | $1.95M | $1.96M | $1.96M | $1.96M | $2.46M | $2.46M | $2.46M | $2.46M | $1.88M | $1.89M | $1.90M | $1.89M |
| Other Non-Current Liabilities | $7.40M | $- | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $88.00K | $3.00M | $3.20M | $3.49M | $3.79M | $4.09M | $4.41M | $4.85M | $5.18M |
| Total Non-Current Liabilities | $13.68M | $11.98M | $12.15M | $13.45M | $10.91M | $10.25M | $10.15M | $10.03M | $10.49M | $10.73M | $10.24M | $7.67M | $10.76M | $11.20M | $12.97M | $13.95M | $13.69M | $13.03M | $11.81M | $11.69M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $26.29M | $26.86M | $29.54M | $29.47M | $23.84M | $23.26M | $23.34M | $21.26M | $21.35M | $22.22M | $24.81M | $21.57M | $23.79M | $25.24M | $24.65M | $22.85M | $23.16M | $23.11M | $19.53M | $21.29M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $0 | $0 | $- | $- | $- | $26.00K | $- |
| Common Stock | $54.00K | $54.00K | $54.00K | $54.00K | $54.00K | $53.00K | $53.00K | $53.00K | $53.00K | $53.00K | $53.00K | $53.00K | $53.00K | $53.00K | $52.00K | $52.00K | $52.00K | $52.00K | $52.00K | $52.00K |
| Retained Earnings | $32.67M | $29.52M | $27.54M | $26.39M | $26.16M | $24.90M | $25.68M | $25.66M | $25.66M | $25.66M | $24.75M | $24.86M | $24.84M | $21.15M | $20.16M | $17.29M | $16.58M | $15.03M | $14.60M | $14.64M |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $- | $-0 | $-0 | $-0 | $-0 | $-0 | $0 | $-0 | $-0 | $-0 | $-0 | $-0 | $-0 | $-0 | $-0 | $-0 | $-26.00K | $-10.00K |
| Other Total Stockholders Equity | $7.61M | $7.61M | $7.72M | $7.71M | $7.60M | $7.51M | $7.42M | $7.34M | $7.21M | $7.08M | $6.96M | $6.83M | $6.56M | $6.47M | $6.34M | $6.30M | $6.14M | $6.14M | $6.14M | $6.14M |
| Total Stockholders Equity | $40.34M | $37.18M | $35.31M | $34.16M | $33.82M | $32.46M | $33.16M | $33.05M | $32.92M | $32.79M | $31.76M | $31.75M | $31.45M | $27.67M | $26.56M | $23.65M | $22.77M | $21.22M | $20.77M | $20.82M |
| Total Equity | $40.34M | $37.18M | $35.31M | $34.16M | $33.82M | $32.46M | $33.16M | $33.05M | $32.92M | $32.79M | $31.76M | $31.75M | $31.45M | $27.67M | $26.56M | $23.65M | $22.77M | $21.22M | $20.77M | $20.82M |
| Total Liabilities and Stockholders Equity | $66.63M | $64.05M | $64.85M | $63.63M | $57.65M | $55.72M | $56.50M | $54.31M | $54.28M | $55.01M | $56.57M | $53.33M | $55.25M | $52.92M | $51.21M | $46.50M | $45.93M | $44.33M | $40.30M | $42.12M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $66.63M | $64.05M | $64.85M | $63.63M | $57.65M | $55.72M | $56.50M | $54.31M | $54.28M | $55.01M | $56.57M | $53.33M | $55.25M | $52.92M | $51.21M | $46.50M | $45.93M | $44.33M | $40.30M | $42.12M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.24M | $1.24M | $1.23M | $1.23M | $1.21M | $1.19M | $1.16M | $1.18M |
| Total Debt | $5.29M | $5.44M | $5.61M | $5.77M | $5.94M | $6.12M | $6.29M | $6.47M | $6.71M | $6.88M | $7.06M | $4.40M | $4.60M | $7.46M | $7.71M | $7.92M | $8.10M | $8.36M | $5.86M | $5.39M |
| Net Debt | $-3.72M | $-1.85M | $-1.20M | $-3.40M | $93.00K | $1.39M | $2.36M | $-256.00K | $-4.10M | $-5.54M | $-7.76M | $-9.09M | $-10.40M | $-5.73M | $-4.83M | $-840.00K | $646.00K | $3.95M | $3.67M | $4.02M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $795.00K | $800.00K | $7.57M | $2.67M | $1.96M |
| Depreciation and Amortization | $2.40M | $2.88M | $2.67M | $2.41M | $1.79M |
| Deferred Income Tax | $-434.00K | $130.00K | $-506.00K | $575.00K | $459.00K |
| Stock Based Compensation | $375.00K | $505.00K | $531.00K | $163.00K | $270.00K |
| Change in Working Capital | $4.96M | $-10.88M | $1.83M | $1.76M | $-622.00K |
| Accounts Receivables | $-68.00K | $-6.55M | $-255.00K | $2.86M | $-561.00K |
| Inventory | $-1.35M | $-973.00K | $-651.00K | $48.00K | $1.32M |
| Accounts Payables | $1.52M | $3.75M | $205.00K | $-1.31M | $-1.03M |
| Other Working Capital | $4.86M | $-7.10M | $2.53M | $169.00K | $-347.00K |
| Other Non Cash Items | $-366.00K | $235.00K | $-2.97M | $-92.00K | $73.00K |
| Net Cash Provided by Operating Activities | $7.73M | $-6.33M | $9.13M | $7.49M | $3.93M |
| Investments in Property Plant and Equipment | $-5.01M | $-2.75M | $-5.37M | $-2.63M | $-4.87M |
| Acquisitions Net | $- | $118.00K | $489.00K | $235.00K | $162.00K |
| Purchases of Investments | $- | $- | $-23.00K | $-29.00K | $-32.00K |
| Sales Maturities of Investments | $- | $- | $1.25M | $-235.00K | $-162.00K |
| Other Investing Activities | $346.00K | $118.00K | $1.71M | $235.00K | $162.00K |
| Net Cash Used for Investing Activities | $-4.66M | $-2.63M | $-3.65M | $-2.42M | $-4.74M |
| Debt Repayment | $-619.00K | $2.22M | $-744.00K | $2.62M | $508.00K |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $-282.00K | $-281.00K |
| Other Financing Activities | $- | $-25.00K | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $-619.00K | $2.20M | $-744.00K | $2.33M | $227.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $2.45M | $-6.77M | $4.73M | $7.40M | $-582.00K |
| Cash at End of Period | $9.18M | $6.73M | $13.49M | $8.76M | $1.36M |
| Cash at Beginning of Period | $6.73M | $13.49M | $8.76M | $1.36M | $1.95M |
| Operating Cash Flow | $7.73M | $-6.33M | $9.13M | $7.49M | $3.93M |
| Capital Expenditure | $-5.01M | $-2.75M | $-5.37M | $-2.63M | $-4.87M |
| Free Cash Flow | $2.72M | $-9.08M | $3.76M | $4.86M | $-939.00K |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $3.15M | $1.98M | $1.15M | $230.00K | $1.27M | $-781.00K | $80.00K | $4.00K | $5.00K | $910.00K | $-119.00K | $24.00K | $3.69M | $985.00K | $2.87M | $713.00K | $1.55M | $441.00K | $-38.00K | $781.00K |
| Depreciation and Amortization | $702.00K | $653.00K | $641.00K | $583.00K | $619.00K | $582.00K | $594.00K | $754.00K | $727.00K | $697.00K | $703.00K | $695.00K | $658.00K | $672.00K | $646.00K | $621.00K | $611.00K | $608.00K | $572.00K | $472.00K |
| Deferred Income Tax | $1.00K | $-1.00K | $-1.00K | $-434.00K | $-96.00K | $95.00K | $1.00K | $135.00K | $-5.00K | $-5.00K | $5.00K | $-503.00K | $1.00K | $- | $-4.00K | $580.00K | $-8.00K | $-13.00K | $16.00K | $458.00K |
| Stock Based Compensation | $5.00K | $30.00K | $5.00K | $114.00K | $90.00K | $86.00K | $85.00K | $126.00K | $126.00K | $127.00K | $126.00K | $273.00K | $86.00K | $131.00K | $41.00K | $163.00K | $- | $- | $1.00K | $47.00K |
| Change in Working Capital | $250.00K | $-118.00K | $-2.36M | $3.82M | $675.00K | $2.80M | $-2.33M | $-4.35M | $-1.43M | $-3.21M | $-1.90M | $1.09M | $292.00K | $-342.00K | $790.00K | $-495.00K | $1.26M | $272.00K | $725.00K | $-804.00K |
| Accounts Receivables | $-412.00K | $2.63M | $-3.10M | $815.00K | $-168.00K | $1.34M | $-1.80M | $-3.39M | $-463.00K | $-636.00K | $-2.06M | $2.54M | $-756.00K | $-919.00K | $-1.12M | $-54.00K | $1.02M | $-1.36M | $3.26M | $-660.00K |
| Inventory | $426.00K | $283.00K | $-1.80M | $-961.00K | $544.00K | $239.00K | $-1.17M | $166.00K | $-453.00K | $-206.00K | $-480.00K | $351.00K | $-453.00K | $-396.00K | $-153.00K | $-30.00K | $-56.00K | $63.00K | $71.00K | $325.00K |
| Accounts Payables | $29.00K | $-1.55M | $-392.00K | $1.86M | $-208.00K | $-756.00K | $624.00K | $1.24M | $845.00K | $207.00K | $1.45M | $-1.09M | $222.00K | $377.00K | $701.00K | $-633.00K | $-619.00K | $449.00K | $-511.00K | $-59.00K |
| Other Working Capital | $207.00K | $-1.49M | $2.93M | $2.10M | $507.00K | $1.98M | $24.00K | $-2.36M | $-1.36M | $-2.58M | $-809.00K | $-711.00K | $1.28M | $596.00K | $1.37M | $222.00K | $920.00K | $1.12M | $-2.10M | $-410.00K |
| Other Non Cash Items | $-235.00K | $162.00K | $6.38M | $-474.00K | $-173.00K | $-142.00K | $10.00K | $329.00K | $-74.00K | $-11.00K | $-9.00K | $-14.00K | $-2.87M | $-46.00K | $-38.00K | $-73.00K | $-18.00K | $18.00K | $295.00K | $-12.00K |
| Net Cash Provided by Operating Activities | $3.87M | $2.71M | $-777.00K | $4.27M | $2.38M | $2.64M | $-1.55M | $-3.00M | $-648.00K | $-1.49M | $-1.19M | $1.56M | $1.86M | $1.40M | $4.30M | $1.51M | $3.40M | $1.33M | $1.26M | $942.00K |
| Investments in Property Plant and Equipment | $-2.04M | $-1.71M | $-1.79M | $-879.00K | $-1.16M | $-1.81M | $-1.16M | $990.00K | $-1.78M | $-1.77M | $-196.00K | $-4.16M | $-284.00K | $-550.00K | $-376.00K | $-126.00K | $-175.00K | $-1.66M | $-669.00K | $-1.12M |
| Acquisitions Net | $- | $- | $355.00K | $94.00K | $53.00K | $117.00K | $82.00K | $15.00K | $38.00K | $26.00K | $39.00K | $23.00K | $378.00K | $42.00K | $46.00K | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.00K | $-7.00K | $-6.00K | $-7.00K | $-7.00K | $-7.00K | $-7.00K | $-8.00K | $-8.00K |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-23.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $22.00K | $-352.00K | $355.00K | $94.00K | $53.00K | $117.00K | $82.00K | $-1.91M | $921.00K | $988.00K | $39.00K | $1.29M | $378.00K | $42.00K | $46.00K | $91.00K | $73.00K | $30.00K | $41.00K | $17.00K |
| Net Cash Used for Investing Activities | $-2.02M | $-2.06M | $-1.44M | $-785.00K | $-1.10M | $-1.69M | $-1.08M | $-904.00K | $-818.00K | $-752.00K | $-157.00K | $-2.89M | $87.00K | $-514.00K | $-337.00K | $-42.00K | $-109.00K | $-1.63M | $-636.00K | $-1.11M |
| Debt Repayment | $-131.00K | $-159.00K | $-157.00K | $-158.00K | $-155.00K | $-153.00K | $-153.00K | $-152.00K | $-151.00K | $-149.00K | $2.68M | $-177.00K | $-146.00K | $-226.00K | $-195.00K | $-152.00K | $-242.00K | $2.51M | $496.00K | $515.00K |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-282.00K | $- | $- | $-282.00K | $-281.00K |
| Other Financing Activities | $- | $- | $- | $- | $- | $- | $- | $-25.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $281.00K |
| Net Cash Used Provided by Financing Activities | $-131.00K | $-159.00K | $-157.00K | $-158.00K | $-155.00K | $-153.00K | $-153.00K | $-177.00K | $-151.00K | $-149.00K | $2.68M | $-177.00K | $-146.00K | $-226.00K | $-195.00K | $-152.00K | $-242.00K | $2.51M | $214.00K | $515.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.73M | $487.00K | $-2.37M | $3.33M | $1.12M | $791.00K | $-2.79M | $-4.08M | $-1.62M | $-2.39M | $1.33M | $-1.50M | $1.80M | $660.00K | $3.77M | $1.31M | $3.04M | $2.21M | $834.00K | $345.00K |
| Cash at End of Period | $9.01M | $7.29M | $6.80M | $9.18M | $5.85M | $4.73M | $3.94M | $6.73M | $10.81M | $12.43M | $14.82M | $13.49M | $14.99M | $13.19M | $12.53M | $8.76M | $7.45M | $4.40M | $2.20M | $1.36M |
| Cash at Beginning of Period | $7.29M | $6.80M | $9.18M | $5.85M | $4.73M | $3.94M | $6.73M | $10.81M | $12.43M | $14.82M | $13.49M | $14.99M | $13.19M | $12.53M | $8.76M | $7.45M | $4.40M | $2.20M | $1.36M | $1.02M |
| Operating Cash Flow | $3.87M | $2.71M | $-777.00K | $4.27M | $2.38M | $2.64M | $-1.55M | $-3.00M | $-648.00K | $-1.49M | $-1.19M | $1.56M | $1.86M | $1.40M | $4.30M | $1.51M | $3.40M | $1.33M | $1.26M | $942.00K |
| Capital Expenditure | $-2.04M | $-1.71M | $-1.79M | $-879.00K | $-1.16M | $-1.81M | $-1.16M | $990.00K | $-1.78M | $-1.77M | $-196.00K | $-4.16M | $-284.00K | $-550.00K | $-376.00K | $-126.00K | $-175.00K | $-1.66M | $-669.00K | $-1.12M |
| Free Cash Flow | $1.83M | $998.00K | $-2.57M | $3.39M | $1.22M | $827.00K | $-2.72M | $-2.01M | $-2.42M | $-3.26M | $-1.39M | $-2.59M | $1.58M | $850.00K | $3.93M | $1.38M | $3.22M | $-331.00K | $587.00K | $-179.00K |
Smith-Midland Dividends
Explore Smith-Midland's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
1.54x
Smith-Midland Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.055 | $0.055 | December 19, 2019 | December 20, 2019 | January 03, 2020 | December 05, 2019 |
| $0.055 | $0.055 | December 18, 2018 | December 19, 2018 | January 02, 2019 | December 06, 2018 |
| $0.05 | $0.05 | December 26, 2017 | |||
| $0.01 | $0.01 | December 28, 2016 | December 30, 2016 | January 13, 2017 | December 22, 2016 |
| $0.04 | $0.04 | December 16, 2015 | December 18, 2015 | December 30, 2015 | December 03, 2015 |
| $0.035 | $0.035 | December 23, 2014 | December 17, 2014 | December 30, 2014 | December 22, 2014 |
| $0.03 | $0.03 | December 31, 2013 | December 20, 2013 | December 16, 2013 | |
| $0.03 | $0.03 | December 18, 2013 | December 20, 2013 | December 27, 2013 | December 16, 2013 |
| $0.05 | $0.05 | December 21, 2012 | December 14, 2012 | December 31, 2012 | December 20, 2012 |
Smith-Midland News
Read the latest news about Smith-Midland, including recent articles, headlines, and updates.
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference, which is taking place from February 5-6, 2025, in New York, NY.
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference.
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found.
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m.
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time.
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana's website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET.
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York.
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET.
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim's SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY.
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:30 p.m. ET in New York, NY.
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T.
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being held from February 5-6, 2025 in New York. Details of the event are as follows: Date: Wednesday, February.
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings.
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management's fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET.
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY.
Easi-Set Worldwide Signs Building License Agreement with Infrastructure Precast, Inc.
MIDLAND, VA / ACCESS Newswire / January 21, 2025 / Easi-Set Worldwide, a subsidiary of Smith-Midland Corporation (NASDAQ:SMID), is excited to announce a new licensing agreement with Infrastructure Precast Inc. (ICast) of Kentucky. Under this agreement, ICast will produce Easi-Set and Easi-Span precast concrete modular buildings for Kentucky, Middle Tennessee, and Southern Indiana.
Why SMID Cap ETFs Make Sense in a Falling-Rate Environment
Small- and mid-cap (SMID cap) ETFs have seen strong flows recently, making it important that investors fully understand why moving down the cap spectrum can make sense in a falling rate environment. In short, small-and mid-cap stocks, or SMID caps, are more sensitive to interest rates and economic conditions than larger companies.
Smith-Midland to Present and Host 1x1 Investor Meetings at the 16th Annual Southwest IDEAS Investor Conference on November 21st
MIDLAND, VA / ACCESSWIRE / November 15, 2024 / Smith-Midland Corporation (NASDAQ:SMID), a provider of innovative, high-quality proprietary and patented precast concrete products and systems today announced Ashley Smith, Chairman and Chief Executive Officer of Smith-Midland, will present at the Southwest IDEAS Investor Conference on Thursday, November 21, 2024 at The Statler in Dallas, TX. The company's presentation is scheduled to begin at 10:00am CT.
Smith-Midland Reports Third Quarter 2024 Financial Results
Record Quarterly Revenue of $23.6 Million, 51 Percent Increase from Prior Year MIDLAND, VA / ACCESSWIRE / November 14, 2024 / Smith-Midland Corporation (NASDAQ:SMID) a provider of innovative, high-quality proprietary and patented precast concrete products and systems today announced its third quarter results for the period ended September 30, 2024. Third Quarter 2024 Summary (compared to comparable prior-year quarter) Revenue increased 51 percent to $23.6 million Product sales of $10.8 versus $10.9 million Service revenue increased 170 percent to $12.8 million Operating income of $3.8 million, compared to $1.5 million Net income of $3.2 million, or $0.59 per diluted share, compared to $1.3 million or $0.24 per diluted share Awarded provisional patent and successfully crash tested J-J Hook MASH 16 Low-Profile Barrier "Our third quarter was a record-setter for both revenue and net income, driven by the tailwinds within our sector and multiple special barrier projects, occurring and completed in the quarter, which have a more favorable margin profile," said Ashley Smith, Chairman and Chief Executive Officer of Smith-Midland.
Comparing SMID INTL Equity ETFs: Sell GWX, Buy DFIS
International Small Cap stocks currently offer better valuation compared to US Small-Cap stocks, as indicated by ETF comparisons. GWX ranks last in the Foreign Small/Mid Blend category, earning a Strong Sell rating due to poor relative performance. DFIS, the top-ranked ETF gets a Buy rating. This article reviews both GWX's and DFIS's current holdings, and then explores the reason why their returns vary so much.
Diversify Your SMID Exposure With Actively-Managed NBSM
Investors looking to the potential of small- and midcap (SMID) performance in a declining rate environment would do well to consider the Neuberger Berman Small-Mid Cap ETF (NBSM). The actively managed fund offers diversified exposure when compared to the Russell 2500 Index benchmark.
Similar Companies
Loma Negra Compañía Industrial Argentina Sociedad Anónima
LOMA
Price: $10.97
Market Cap: $1.28B
Related Metrics
Explore detailed financial metrics and analysis for SMID.